Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Jacksonville, Florida Clear all
Completed No phase listed Observational

A Registry for Patients Taking Uptravi

NCT03278002
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process

NCT05427539
View directory record Official record
Conditions
Ocular Physiology
Interventions
TEST LENS, CONTROL LENS
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
6
States / cities
Jacksonville, Florida • Maitland, Florida • Vestal, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Wholetones® 2Sleep Music on Health and Sleep Behaviors of Healthy Adults With Insomnia Symptoms

NCT03928301
View directory record Official record
Conditions
Insomnia, Sleeplessness
Interventions
Wholetones Music, Classical Music
Behavioral
Lead sponsor
Jacksonville University
Other
Eligibility
25 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

NCT02730819
View directory record Official record
Conditions
Melasma
Interventions
Illuminate Cream
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 3 Interventional

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

NCT06401330
View directory record Official record
Conditions
Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor, Stage IV Mixed Cell Type Kidney Wilms Tumor
Interventions
Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Magnetic Resonance Imaging, Nephrectomy, Patient Observation, Positron Emission Tomography, Ultrasound Imaging, Vincristine, X-Ray Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
146
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 123 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Anterior Referencing Versus Posterior Referencing in Minimally Invasive Total Knee Arthroplasty

NCT01135030
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total knee
Procedure
Lead sponsor
Heekin Orthopedic Research Institute
Other
Eligibility
21 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2012 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

NCT00003830
View directory record Official record
Conditions
Breast Cancer
Interventions
conventional surgery, Sentinel node resection followed by node examination
Procedure
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
5,611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2014
U.S. locations
68
States / cities
Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Available No phase listed Expanded access

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134
View directory record Official record
Conditions
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Brexucabtagene Autoleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed No phase listed Observational

A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies

NCT00953732
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Lesion count
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Hot Springs, Arizona • Fremont, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional

Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis

NCT01605006
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NeuRx Diaphragm Pacing System (DPS)
Device
Lead sponsor
Synapse Biomedical
Industry
Eligibility
21 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

Low-dose Hormone Therapy for Relief of Vasomotor Symptoms

NCT00446199
View directory record Official record
Conditions
Vasomotor Symptoms, Hot Flashes
Interventions
0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Safety and Efficacy of an Oral Contraceptive

NCT00932321
View directory record Official record
Conditions
Prevention of Pregnancy
Interventions
Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 23, 2026, 2:10 PM EDT
Terminated Not applicable Interventional

Surgical Versus Non-surgical Staging of Lung Cancer

NCT01117714
View directory record Official record
Conditions
Lung Cancer
Interventions
Integrated Staging for Early Detection of Metastases in Lung Cancer
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Jacksonville, Florida • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

LEO 90100 in the Treatment of Psoriasis Vulgaris

NCT01536938
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Calcipotriol, Betamethasone
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Not applicable Interventional Results available

Increasing Activity in Liver Transplant Patients

NCT02058498
View directory record Official record
Conditions
Liver Transplant
Interventions
Physical activity
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

NCT02450552
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ezogabine, Placebo
Drug
Lead sponsor
Brian Wainger
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting No phase listed Observational

Prospective Carotid Artery Stenosis Trial

NCT05724836
View directory record Official record
Conditions
Patients With Any Degree of Carotid Artery Stenosis and Vulnerable Features in the Carotid Artery Plaque
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2023 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 4 Interventional Results available

Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men

NCT00363311
View directory record Official record
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
58
States / cities
Little Rock, Arkansas • Beverly Hills, California • Laguna Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

NCT02935634
View directory record Official record
Conditions
Advanced Gastric Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 1Phase 2 Interventional

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

NCT00397293
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AT-101, topotecan
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Jul 23, 2026, 2:10 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation

NCT00403767
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Embolism
Interventions
Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
14,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
295
States / cities
Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 23, 2026, 2:10 PM EDT
Recruiting Phase 3 Interventional

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
45 Years to 99 Years
Enrollment
12,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
139
States / cities
Daphne, Alabama • Fairhope, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 2:10 PM EDT